174 related articles for article (PubMed ID: 36518314)
1. Reduced tumor stiffness quantified by tomoelastography as a predicative marker for glypican-3-positive hepatocellular carcinoma.
Wang Y; Guo J; Ma D; Zhou J; Yang Y; Chen Y; Wang H; Sack I; Li R; Yan F
Front Oncol; 2022; 12():962272. PubMed ID: 36518314
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional multifrequency magnetic resonance elastography improves preoperative assessment of proliferative hepatocellular carcinoma.
Liu G; Ma D; Wang H; Zhou J; Shen Z; Yang Y; Chen Y; Sack I; Guo J; Li R; Yan F
Insights Imaging; 2023 May; 14(1):89. PubMed ID: 37198348
[TBL] [Abstract][Full Text] [Related]
3. Tomoelastography based on multifrequency MR elastography predicts liver function reserve in patients with hepatocellular carcinoma: a prospective study.
Lin H; Wang Y; Zhou J; Yang Y; Xu X; Ma D; Chen Y; Yang C; Sack I; Guo J; Li R; Yan F
Insights Imaging; 2022 Jun; 13(1):95. PubMed ID: 35657534
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI combined with clinical factors to predict glypican-3 expression of hepatocellular carcinoma.
Liu P; Li W; Qiu G; Chen J; Liu Y; Wen Z; Liang M; Zhao Y
Front Oncol; 2023; 13():1142916. PubMed ID: 38023195
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma.
Zhao J; Gao S; Sun W; Grimm R; Fu C; Han J; Sheng R; Zeng M
Eur J Radiol; 2021 Jun; 139():109732. PubMed ID: 33905978
[TBL] [Abstract][Full Text] [Related]
7. Tomoelastography Based on Multifrequency MR Elastography for Prostate Cancer Detection: Comparison with Multiparametric MRI.
Li M; Guo J; Hu P; Jiang H; Chen J; Hu J; Asbach P; Sack I; Li W
Radiology; 2021 May; 299(2):362-370. PubMed ID: 33687285
[TBL] [Abstract][Full Text] [Related]
8. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
9. [The value of serum glypican-3 level in aided diagnosis of patients with primary hepatocellular carcinoma].
Tang XY; Wang YC; Lu RQ; Guo L
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):998-1002. PubMed ID: 32907292
[No Abstract] [Full Text] [Related]
10. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
11. Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.
Li N; Dong T; Wang P; Li Q; Nie F
Clin Hemorheol Microcirc; 2023; 85(4):407-420. PubMed ID: 37638421
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis.
Jia X; Liu J; Gao Y; Huang Y; Du Z
Arch Med Res; 2014 Oct; 45(7):580-8. PubMed ID: 25446613
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma.
Nakatsura T; Nishimura Y
BioDrugs; 2005; 19(2):71-7. PubMed ID: 15807627
[TBL] [Abstract][Full Text] [Related]
15. A Single-Step Immunocapture Assay to Quantify HCC Exosomes Using the Highly Sensitive Fluorescence Nanoparticle-Tracking Analysis.
Koksal AR; Ekmen N; Aydin Y; Nunez K; Sandow T; Delk M; Moehlen M; Thevenot P; Cohen A; Dash S
J Hepatocell Carcinoma; 2023; 10():1935-1954. PubMed ID: 37936599
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer.
Liu S; Wang M; Zheng C; Zhong Q; Shi Y; Han X
Clin Biochem; 2020 May; 79():54-60. PubMed ID: 32087138
[TBL] [Abstract][Full Text] [Related]
17. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Gomaa SH; Abaza MM; Elattar HA; Amin GA; Elshahawy DM
Arab J Gastroenterol; 2020 Dec; 21(4):224-232. PubMed ID: 32891543
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
20. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
Xu C; Yan Z; Zhou L; Wang Y
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1417-24. PubMed ID: 23743582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
